Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety.

Wiedermann CJ, Hoffmann JN, Juers M, Ostermann H, Kienast J, Briegel J, Strauss R, Keinecke HO, Warren BL, Opal SM; KyberSept Investigators.

Crit Care Med. 2006 Feb;34(2):285-92.

PMID:
16424704
2.

Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.

Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Pénzes I, Kübler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM; KyberSept Trial Study Group.

JAMA. 2001 Oct 17;286(15):1869-78. Erratum in: JAMA 2002 Jan 9;287(2):192.

PMID:
11597289
3.

Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023].

Rublee D, Opal SM, Schramm W, Keinecke HO, Knaub S.

Crit Care. 2002 Aug;6(4):349-56. Epub 2002 Jun 24.

4.
5.

Activity-guided antithrombin III therapy in severe surgical sepsis: efficacy and safety according to a retrospective data analysis.

Moubarak P, Zilker S, Wolf H, Hofner B, Kneib T, Küchenhoff H, Jauch KW, Hartl WH.

Shock. 2008 Dec;30(6):634-41. doi: 10.1097/SHK.0b013e31817d3e14.

PMID:
18520701
6.

Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin.

Hoffmann JN, Wiedermann CJ, Juers M, Ostermann H, Kienast J, Briegel J, Strauss R, Warren BL, Opal SM; KyberSept investigators.

Thromb Haemost. 2006 May;95(5):850-6.

PMID:
16676077
7.

Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study.

Baudo F, Caimi TM, de Cataldo F, Ravizza A, Arlati S, Casella G, Carugo D, Palareti G, Legnani C, Ridolfi L, Rossi R, D'Angelo A, Crippa L, Giudici D, Gallioli G, Wolfler A, Calori G.

Intensive Care Med. 1998 Apr;24(4):336-42.

PMID:
9609411
8.

Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation.

Kienast J, Juers M, Wiedermann CJ, Hoffmann JN, Ostermann H, Strauss R, Keinecke HO, Warren BL, Opal SM; KyberSept investigators.

J Thromb Haemost. 2006 Jan;4(1):90-7.

9.

Early administration of high-dose antithrombin in severe sepsis: single center results from the KyberSept-trial.

Eid A, Wiedermann CJ, Kinasewitz GT.

Anesth Analg. 2008 Nov;107(5):1633-8. doi: 10.1213/ane.0b013e318184621d.

PMID:
18931224
10.

Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study.

Abraham E, Reinhart K, Svoboda P, Seibert A, Olthoff D, Dal Nogare A, Postier R, Hempelmann G, Butler T, Martin E, Zwingelstein C, Percell S, Shu V, Leighton A, Creasey AA.

Crit Care Med. 2001 Nov;29(11):2081-9.

PMID:
11700399
11.

Antithrombin III in patients with severe sepsis: a pharmacokinetic study.

Ilias W, List W, Decruyenaere J, Lignian H, Knaub S, Schindel F, Keinecke HO, Heinrichs H, Thijs LG.

Intensive Care Med. 2000 Jun;26(6):704-15.

PMID:
10945387
12.

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, François B, Guy JS, Brückmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group.

N Engl J Med. 2005 Sep 29;353(13):1332-41.

13.

Lipoprotein metabolism in patients with severe sepsis.

van Leeuwen HJ, Heezius EC, Dallinga GM, van Strijp JA, Verhoef J, van Kessel KP.

Crit Care Med. 2003 May;31(5):1359-66.

PMID:
12771603
14.

[Antithrombin therapy of no value in sepsis according to a large clinical trial].

Gårdlund B.

Lakartidningen. 2002 Mar 27;99(13):1456-7, 1460. Review. Swedish.

PMID:
11989356
15.

Selenium in Intensive Care (SIC): results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock.

Angstwurm MW, Engelmann L, Zimmermann T, Lehmann C, Spes CH, Abel P, Strauss R, Meier-Hellmann A, Insel R, Radke J, Schüttler J, Gärtner R.

Crit Care Med. 2007 Jan;35(1):118-26.

PMID:
17095947
16.

Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.

Tidswell M, Tillis W, Larosa SP, Lynn M, Wittek AE, Kao R, Wheeler J, Gogate J, Opal SM; Eritoran Sepsis Study Group.

Crit Care Med. 2010 Jan;38(1):72-83. doi: 10.1097/CCM.0b013e3181b07b78. Erratum in: Crit Care Med. 2010 Sep;38(9):1925-6. Multiple investigator names added..

PMID:
19661804
17.

Antithrombin III in Sepsis. New evidences and open questions.

Ostermann H.

Minerva Anestesiol. 2002 May;68(5):445-8. Review.

18.

Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group.

Dhainaut JF, Tenaillon A, Hemmer M, Damas P, Le Tulzo Y, Radermacher P, Schaller MD, Sollet JP, Wolff M, Holzapfel L, Zeni F, Vedrinne JM, de Vathaire F, Gourlay ML, Guinot P, Mira JP.

Crit Care Med. 1998 Dec;26(12):1963-71.

PMID:
9875905
19.

Effect of long-term and high-dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis.

Hoffmann JN, Mühlbayer D, Jochum M, Inthorn D.

Crit Care Med. 2004 Sep;32(9):1851-9.

PMID:
15343012
20.

Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.

Abraham E, Laterre PF, Garbino J, Pingleton S, Butler T, Dugernier T, Margolis B, Kudsk K, Zimmerli W, Anderson P, Reynaert M, Lew D, Lesslauer W, Passe S, Cooper P, Burdeska A, Modi M, Leighton A, Salgo M, Van der Auwera P; Lenercept Study Group.

Crit Care Med. 2001 Mar;29(3):503-10.

PMID:
11373411

Supplemental Content

Support Center